Literature DB >> 975725

Gastric and biliary excretion of meperidine in man.

R Dunkerley, R Johnson, S Schenker, G R Wilkinson.   

Abstract

The role and importance of enterogastric secretion in the disposition and elimination of the weak base, meperidine (pKa 8.63), was studied after intravenous administration (50 mg) of the drug to 6 normal volunteers. Continuous collection of the gastric fluid over a 4-hr period demonstrated the establishment of high gastric fluid/plasma concentration ratios for meperidine (mean about 50, range, 10 to 200). However, the total amount of drug recovered, even after correction for incomplete collection, was only a small percentage of the administered dose. Under basal conditions a mean +/- SE of 1.9 +/- 0.3 mg, equivalent to 3.7% of the administered dose, was found in the total gastric aspirate. Stimulation of gastric secretion by subcutaneous injection of betazole (1.5 mg/kg) increased this recovery to 3.6 +/- 0.3 mg (7.2%) primarily due to the increase in gastric volumen output. Aspiration of the gastric fluid in either the basal or stimulated situation had no observable effect upon the plasma concentration/time profile of meperidine whether assessed by the terminal half-life, t 1/2 beta, or the plasma clearance; control values were 3.8 +/- hr and 1,190 +/- 130 ml/min, respectively. In 2 subjects "bile fluid" was also collected for 2.5 hr and found to contain less than 0.2% of the administered dose. Enterosystemic recycling is therefore of minor importance in the disposition and elimination of meperidine in man.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 975725     DOI: 10.1002/cpt1976205546

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  8 in total

Review 1.  Enterohepatic circulation: physiological, pharmacokinetic and clinical implications.

Authors:  Michael S Roberts; Beatrice M Magnusson; Frank J Burczynski; Michael Weiss
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

2.  Drug kinetics and artificial kidneys.

Authors:  T B Gibson; H A Nelson
Journal:  Clin Pharmacokinet       Date:  1977 Nov-Dec       Impact factor: 6.447

Review 3.  Intravenous anaesthetic agents. Pharmacokinetic-pharmacodynamic relationships.

Authors:  B N Swerdlow; F O Holley
Journal:  Clin Pharmacokinet       Date:  1987-02       Impact factor: 6.447

Review 4.  Clinical pharmacokinetics of pethidine.

Authors:  L E Mather; P J Meffin
Journal:  Clin Pharmacokinet       Date:  1978 Sep-Oct       Impact factor: 6.447

5.  Patient-controlled analgesic therapy. Part I: Pharmacokinetics of pethidine in the per- and postoperative periods.

Authors:  A Tamsen; P Hartvig; C Fagerlund; B Dahlström
Journal:  Clin Pharmacokinet       Date:  1982 Mar-Apr       Impact factor: 6.447

Review 6.  Biliary excretion of drugs in man.

Authors:  D E Rollins; C D Klaassen
Journal:  Clin Pharmacokinet       Date:  1979 Sep-Oct       Impact factor: 6.447

Review 7.  Clinical pharmacokinetics of fentanyl and its newer derivatives.

Authors:  L E Mather
Journal:  Clin Pharmacokinet       Date:  1983 Sep-Oct       Impact factor: 6.447

8.  Clinical pharmacokinetics and oral bioavailability of ketobemidone.

Authors:  U Bondesson; S Arnér; P Anderson; L O Boréus; P Hartvig
Journal:  Eur J Clin Pharmacol       Date:  1980-01       Impact factor: 2.953

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.